Log In
Print this Print this

Viekira Pak, ombitasvir/paritaprevir/ritonavir plus dasabuvir

Also known as: Holkira Pak (paritaprevir (ABT-450)/ritonavir/ombitasvir (ABT-267) plus dasabuvir (ABT-333))

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionTablets containing ombitasvir, an HCV NS5A protein inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, and ritonavir, an HIV protease inhibitor, co-packaged with dasabuvir, a non-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHIV protease inhibitor; HCV non-structural protein 5A inhibitor; HCV non-structural protein 5B inhibitor; HCV NS3 protease inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection with and without compensated cirrhosis; Treat HCV genotype 1 infection with compensated cirrhosis
Regulatory Designation
PartnerEnanta Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today